Day: April 11, 2024

Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market

$59 million financing includes participation from new Icelandic institutional and existing investors; Extends cash runway until 2H 2026 The Central Bank of Iceland, Financial Supervision has approved Oculis’s prospectus related to the admission of its ordinary shares to trade on the Nasdaq Iceland Main Market; Oculis will announce the first day of trading with at least one day advance notice On-track to report topline data from OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED) in Q2 2024 ZUG, Switzerland, April 11, 2024 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis” or the “Company”), today announced that on April 11, 2024 it completed a financing of approximately $59 million, consisting of the issuance of 5,000,000 of its ordinary shares, nominal value CHF 0.01 per share (the...

Continue reading

Northern Technologies International Corporation Reports Financial Results for Second Quarter Fiscal 2024

MINNEAPOLIS, April 11, 2024 (GLOBE NEWSWIRE) — Northern Technologies International Corporation (NASDAQ: NTIC), a leading developer of corrosion inhibiting products and services, as well as bio-based and biodegradable polymer resin compounds, today reported its financial results for the second quarter of fiscal 2024. Second quarter fiscal 2024 financial and operating highlights include (with growth rates on a fiscal quarter year-over-year basis): Consolidated net sales increased 14.1% to a second quarter record of $20,843,000 ZERUST® industrial net sales increased 3.1% to a second quarter record of $13,051,000 ZERUST® oil and gas net sales increased 20.1% to a second quarter record $2,167,000 Natur-Tec® product net sales increased 47.5% to a quarterly record of $5,624,000 NTIC China net sales increased 20.3% to $3,456,000 Gross...

Continue reading

Acceleware to Commence Next Phase of Mining Project: CTI-Powered Potash Ore Drying with Saskatchewan’s International Minerals Innovation Institute

CALGARY, Alberta, April 11, 2024 (GLOBE NEWSWIRE) — Acceleware Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of transformative technologies targeting the decarbonization of industrial heating, is pleased to announce that it has been awarded Phase 2 of a potash ore drying project by the International Minerals Innovation Institute (IMII). The new project phase will advance Phase 1 work and is intended to further validate the use of radio frequency (RF) energy from Acceleware’s Clean Tech Inverter (CTI) to dry potash ore and other minerals. IMII is a non-profit organization jointly funded by industry and government that is committed to developing and implementing innovative education, training, research and development partnerships for supporting a world-class minerals industry. IMII’s minerals industry members...

Continue reading

Results of Audited Activities for the Year 2023 of Panevezio Statybos Trestas AB and Panevezio Statybos Trestas AB Group

In 2023, the consolidated revenue of the Group of Panevezio statybos trestas AB amounted to 119.828 mln. Euros, whereas in 2022 the consolidated revenue was 115.84 mln. Euros. Over the reporting period, the net profit of the Group amounted to 3.322 mln. Euros and in 2022 the Group had the net profit in the amount of 0.525 mln. Euros.Over the year of 2023, the turnover of Panevezio statybos trestas AB amounted to 80.751 mln. Euros, and in 2022 the turnover of Panevezio statybos trestas AB was 79.222 mln. Euros. In 2023, Panevezio statybos trestas AB has suffered the net loss in the amount of 2.279 mln. Euros, the net loss in 2022 was 1.720 mln. Euros. More information:Managing DirectorTomas StukasTel.: +370 618 21360

Continue reading

SciSparc to Acquire AutoMax

TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signed a merger agreement (the “Agreement”) with AutoMax Motors Ltd. (“AutoMax”), a leading vehicle importer company in Israel. According to the Agreement, the Company will acquire 100% of AutoMax and establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into AutoMax (the “Acquisition”). Following the Acquisition, it is contemplated that SciSparc shareholders will hold together approximately 50.01% of the share capital of the post-closing combined company (the “Combined Company”). The Acquisition...

Continue reading

Complete Solaria Update: Operational Progress & PE Debt

FREMONT, Calif., April 11, 2024 (GLOBE NEWSWIRE) — Complete Solaria, Inc. (“Complete Solaria” or the “Company”) (Nasdaq: CSLR) today reported on its current financial status, which includes progress on its cash burn rate, and the status of its debt with private equity firms Kline-Hill Partners and Carlyle, which together hold about $70 million in debt owed on about $35 million of principal, split roughly equally between the two (see our 10K for exact numbers). First, we report on our progress in turning Complete Solaria (CSLR) around financially, starting with our dramatic headcount reduction from 428 to 109 (-74.5%) in seven rounds of layoffs. These layoffs were very unfortunate, but necessary for survival. And when any company keeps only the top 25% of its employees, it winds up with an excellent workforce. Yesterday, our board...

Continue reading

Maris-Tech to Showcase Its Innovative Solutions at the Special Operations Forces Week

The annual conference for U.S. and international special operations forces is expected to host more than 15,000 attendees Rehovot, Israel, April 11, 2024 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a B2B provider of AI accelerated video solutions for edge platforms, today announced its participation in the upcoming Special Operations Forces (SOF) Week, which will take place from May 6 to May 9, 2024,in Tampa, Florida. The Company will demonstrate the capabilities of its innovative solutions with AI acceleration capabilities suitable for professional and tactical operations. Particularly, the Company will showcase its flagship product Jupiter AI, a high-end multiple-stream video platform that can be mounted on diverse autonomous platforms, as well as its Opal tactical edge computing...

Continue reading

NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs

The Company’s neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer’s Phase 2 trial and anticipation of Parkinson’s Phase 1/2a trial initiation. Additional financing also to support the Company’s oncology clinical program, with interim safety data readout in Q2 for its allogeneic product candidate. SANTA ANA, Calif., April 11, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced that it has closed $5 million in second lien convertible loan funding with a term of 30 months, augmenting approximately $4.75 in gross cash proceeds from prior 2024 funding to date. Outstanding...

Continue reading

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities. Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma. WARREN, N.J., April 11, 2024 (GLOBE NEWSWIRE) —  Tevogen Bio Holdings (Tevogen) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer, explains the company’s oncology pipeline strategy. “CTLs can be used for cancer treatments in several ways. Certain cancers are virally driven and can be targeted...

Continue reading

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety and efficacy topline analysis includes sequential organ failure assessment (SOFA) scores and mortality for the 28-day period post treatment. Efficacy: Stand-alone analysis of the Allocetra™-treated patients, of which 78% had septic shock and 65% had invasive ventilation at screening, demonstrated substantial reductions in SOFA scores and 65% reduction in overall mortality rate as compared with expected mortality2.  By day 28, the analysis showed 90% reductions of SOFA scores for sepsis patients whose infection source was urinary tract, 68% for patients whose infection source was community-acquired pneumonia, and 36% for patients whose infection source was internal abdominal infection. Relative analysis...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.